Ken Griffin Allovir, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$0.64 - $0.78 $23,936 - $29,172	37,400 Added 127.65%	66,700 $50,000
Q4 2023 Feb 14, 2024	BUY	$0.68 - $2.39 $14,416 - $50,668	21,200 Added 261.73%	29,300 $19,000
Q3 2023 Nov 14, 2023	SELL	$2.15 - $3.64 $21,715 - $36,764	-10,100 Reduced 55.49%	8,100 $17,000
Q2 2023 Aug 14, 2023	SELL	$3.17 - $5.82 $67,838 - $124,548	-21,400 Reduced 54.04%	18,200 $61,000
Q1 2023 May 15, 2023	BUY	$3.94 - $7.05 $91,014 - $162,855	23,100 Added 140.0%	39,600 $156,000

Q4 2022 Feb 14, 2023	SELL	$4.7 - $9.98 $26,790 - $56,886	-5,700 Reduced 25.68%	16,500 $84,000
Q3 2022 Nov 14, 2022	SELL	$4.13 - $8.79 $2,065 - $4,395	-500 Reduced 2.2%	22,200 $175,000

49.1M

385K

2.3K

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $71.7M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.